{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hsieh MT"],"funding":["Ministry of Science and Technology","Drug Development Center, China Medical University","China Medical University"],"pagination":["12190"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10418893"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(15)"],"pubmed_abstract":["Drug combination therapy is a key approach in cancer treatments, aiming to improve therapeutic efficacy and overcome drug resistance. Evaluation of intracellular response in cancer cells to drug treatment may disclose the underlying mechanism of drug resistance. In this study, we aimed to investigate the effect of osimertinib, a tyrosine kinase inhibitor (TKI), and a curcumin derivative, 35d, on HCC827 cells and tumors by analyzing alterations in metabolome and related regulations. HCC827 tumor-bearing SCID mice and cultured HCC827 cells were separately examined. The treatment comprised four conditions: vehicle-only, 35d-only, osimertinib-only, and a combination of 35d and osimertinib. The treated tumors/cells were subsequently subjected to metabolomics profiling, fatty acyl analysis, mito"],"journal":["International journal of molecular sciences"],"pubmed_title":["The Effects of a Curcumin Derivative and Osimertinib on Fatty Acyl Metabolism and Mitochondrial Functions in HCC827 Cells and Tumors."],"pmcid":["PMC10418893"],"funding_grant_id":["CMU109-MF-102","MOST 107-2311-B-039-001-","CMU111-S-37","MOST 105-2311-B-039-003-MY2","CMU109-S-11","MOST 109-2311-B-039-001","CMU110-S-23","MOST 108-2311-B-039-001-","CMU108-YTY-03"],"pubmed_authors":["Chiang YT","Lee DY","Lee PC","Lin HY","Hsieh MT"],"additional_accession":[]},"is_claimable":false,"name":"The Effects of a Curcumin Derivative and Osimertinib on Fatty Acyl Metabolism and Mitochondrial Functions in HCC827 Cells and Tumors.","description":"Drug combination therapy is a key approach in cancer treatments, aiming to improve therapeutic efficacy and overcome drug resistance. Evaluation of intracellular response in cancer cells to drug treatment may disclose the underlying mechanism of drug resistance. In this study, we aimed to investigate the effect of osimertinib, a tyrosine kinase inhibitor (TKI), and a curcumin derivative, 35d, on HCC827 cells and tumors by analyzing alterations in metabolome and related regulations. HCC827 tumor-bearing SCID mice and cultured HCC827 cells were separately examined. The treatment comprised four conditions: vehicle-only, 35d-only, osimertinib-only, and a combination of 35d and osimertinib. The treated tumors/cells were subsequently subjected to metabolomics profiling, fatty acyl analysis, mito","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jul","modification":"2026-04-08T13:57:30.96Z","creation":"2024-12-04T05:23:24.918Z"},"accession":"S-EPMC10418893","cross_references":{"pubmed":["37569564"],"doi":["10.3390/ijms241512190"]}}